Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?
Noor Ul Ain Rehman
Tue, August 11, 2026 at 3:09 AM GMT+5:30
6 min read
- LLY
+3.90% - NVO
+0.99% - NVO
+0.99%
The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one of healthcare’s fastest-growing markets
Yet another competitive advantage for investors to keep in mind is manufacturing
During the early stages of the GLP-1 boom, demand consistently exceeded supply. Shortages of Wegovy, Ozempic, Mounjaro, and Zepbound demonstrated that developing a breakthrough medicine is only part of the challenge. Companies must also manufacture those medicines reliably, expand production fast enough to meet demand, and build enough capacity to support the next generation of therapies
That raises an important question for investors. As the obesity market matures, will the competitive advantage belong to the company with the strongest drugs, or the one with the strongest manufacturing platform?
A specialized research team in white lab coats working together on a breakthrough biotechnological discovery
Bull Case
Eli Lilly (NYSE:LLY) increasingly appears to view manufacturing as a long-term competitive advantage rather than simply a production necessity. Over the past several years, the company has committed tens of billions of dollars to expanding its manufacturing footprint across the United States. Rather than concentrating on a single facility, Lilly (NYSE:LLY) is investing across multiple manufacturing technologies, including active pharmaceutical ingredients, injectable medicines, and advanced therapies. This broader approach could give the company flexibility not only to support current demand for Mounjaro and Zepbound but also to manufacture future pipeline assets as they reach commercialization.
That flexibility may become increasingly valuable. Today’s obesity market is dominated by injectable therapies, but Lilly’s (NYSE:LLY) pipeline extends well beyond its current products. Building capacity across multiple technologies today reduces the likelihood that manufacturing becomes a bottleneck tomorrow. The strategy also creates optionality beyond obesity. Manufacturing assets developed for peptide medicines, biologics, and advanced therapies can potentially support a much broader pharmaceutical portfolio. In other words, Lilly (NYSE:LLY) is investing in infrastructure that could generate value long after today’s GLP-1 supply constraints disappear.
